Biotech Stocks on Investors' Radar -- Editas, Intra-Cellular, Aralez Pharma, and Catabasis Pharma

Tuesday, March 21, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, March 21, 2017 /PRNewswire/ --

On Monday, benchmark US indices were in mixed colors as the NASDAQ Composite

closed the trading session up 0.01%; the Dow Jones Industrial Average edged 0.04% lower; and the S&P 500 was down 0.20%. US markets made broad based losses with six out of nine sectors finishing the day in red. Pre-market today,
reviews these four Biotechnology stocks: Editas Medicine Inc. (NASDAQ: EDIT), Intra-Cellular Therapies Inc. (NASDAQ: ITCI), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ), and Catabasis Pharmaceuticals Inc. (NASDAQ: CATB). Learn more about these stocks by accessing their free research reports at:


On Monday, shares in Cambridge, Massachusetts-based Editas Medicine Inc. recorded a trading volume of 1.43 million shares, which was above their three months average volume of 775,730 shares. The stock ended the day 0.49% higher at $22.41. Editas Medicine's stock has gained 32.29% in the past three months. The Company's shares are trading above its 50-day and 200-day moving averages by 8.01% and 13.04%, respectively. Furthermore, shares of Editas Medicine, which operates as a genome editing company, have a Relative Strength Index (RSI) of 48.63. Free research report on EDIT is available at:


New York headquartered Intra-Cellular Therapies Inc.'s stock finished Monday's session 1.98% lower at $14.86, with a total volume of 349,141 shares traded. Intra-Cellular Therapies' shares have gained 11.73% in the past one month. The Company's shares are trading above its 50-day moving average by 4.60%. Shares of Intra-Cellular Therapies, which engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease, have an RSI of 55.47. The complimentary research report on ITCI can be downloaded at:

Aralez Pharma  

Milton, Canada headquartered Aralez Pharmaceuticals Inc.'s stock advanced 4.89%, to close the day at $2.36. The stock recorded a trading volume of 4.48 million shares, which was above its three months average volume of 783,940 shares. Aralez Pharma's shares are trading 41.30% and 46.08% below its 50-day and 200-day moving averages, respectively. Additionally, shares of the Company, which operates as a specialty pharmaceutical company in Canada, Ireland, and the US, have an RSI of 26.83.

On March 15th, 2017, research firm Chardan Capital Markets reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $10 a share to $5.50 a share. Visit us today and access our complete research report on ARLZ at:

Catabasis Pharma  

On Monday, shares in Cambridge, Massachusetts-based Catabasis Pharmaceuticals Inc. ended the session 6.45% lower at $1.45, with a total volume of 1.24 million shares traded. Catabasis Pharma's shares have gained 16.00% in the past one month. The stock is trading 39.29% below its 50-day moving average and 62.03% below its 200-day moving average. Moreover, shares of the Company, which focuses on the discovery, development, and commercialization of therapeutics to treat inflammatory and metabolic diseases, have an RSI of 39.13. Get free access to your research report on CATB at:

Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store